Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde

Information

  • Patent Grant
  • 10577345
  • Patent Number
    10,577,345
  • Date Filed
    Friday, August 10, 2018
    6 years ago
  • Date Issued
    Tuesday, March 3, 2020
    4 years ago
Abstract
Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes. Compound (I) binds to hemoglobin and increases it oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease.
Description
FIELD

Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (Compound (Ia)) and intermediates used in such processes. Compound (Ia) binds to hemoglobin and increases it oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease.


BACKGROUND

Compound (Ia) is disclosed in Example 17 of the International Publication No. WO2013/102142. Compound (Ia) binds to hemoglobin and increases it oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease.


In general, for a compound to be suitable as a therapeutic agent or part of a therapeutic agent, the compound synthesis must be amendable to large scale manufacturing and isolation. The large scale manufacturing and isolation should not impact the physical properties and purity of the compound nor should it negatively impact cost or efficacy of a formulated active ingredient. Accordingly, scale up of manufacturing and isolation may require significant efforts to meet these goals.


SUMMARY

Compound (Ia) has been synthesized by certain methods starting with 2,6-dihydroxbenzaldehyde (compound (1)) where each hydroxyl moiety is protected with an unbranched, straight-chain alkyl or alkoxyalkyl such as, for example, methyl or methoxymethyl. Following installation of the aldehyde group, various methods of deprotection of the hydroxyl group were employed to synthesize compound (1) used in the synthesis and production of Compound (Ia). However, the deprotection processes used lead to unwanted polymerization and decomposition reactions of compound (1)—attributed, in part, to the conditions used for deprotection of the hydroxy groups. The undesired byproducts yield complex mixtures, lower yields of Compound (Ia), and require significant effort to purify Compound (Ia) to a degree acceptable for use as a part of a therapeutic agent, thus rendering the above processes impractical for commercial scale synthesis of Compound (Ia).


Provided herein are processes for the synthesis of Compound (Ia):




embedded image


that employ a protecting group sequence and mild reaction conditions to obtain compound (1) in a manner that suppresses unwanted polymerization and decomposition reactions and enables commercial scale synthesis of Compound (Ia).


In one aspect, provided is a process of synthesizing compound (1):




embedded image


the process comprising:


Step (i): treating a compound of formula (2):




embedded image


where each R is —CH(CH2R1)—OR2 or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl with an acid to provide a compound (1) and wherein R1 is hydrogen or alkyl and R2 is alkyl;


Step (ii): optionally converting compound (1) to Compound (Ia):




embedded image


by reacting compound (1) with a compound of formula (3):




embedded image


where LG is a leaving group under alkylation reacting conditions; and


Step (iii): optionally crystallizing Compound (Ia) from heptane and methyl tert-butyl ether at 40°+/−5° C. to 55+/−5° C., preferably at 45°+/−5° C. to 55+/−5° C.


Further provided herein is a process for synthesizing Compound (Ia), the process comprising performing Steps (i) and (ii) of the first aspect in sequence, including embodiments and subembodiments of aspect 1 described herein, thereby synthesizing Compound (Ia). Further provided herein is a process for synthesizing Compound (Ia), the process comprising performing Steps (i), (ii), and (iii) of the first aspect in sequence, including embodiments and subembodiments of aspect 1 described herein, thereby obtaining Compound (Ia).


Provided herein in a second aspect, is a process of synthesizing a compound of formula (2):




embedded image


the process comprising formylating a compound of formula (4):




embedded image


wherein each R in compounds of formulae (2) and (4) is —CH(CH2R1)—OR2 (where R1 is hydrogen or alkyl and R2 is alkyl) or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl to provide a compound of formula (2) above.


Provided herein in a third aspect, is a process of synthesizing a compound of formula (4):




embedded image


wherein each R is —CH(CH2R1)—OR2 (wherein R1 is hydrogen or alkyl and R2 is alkyl) or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl, the process comprising:


reacting compound (5):




embedded image


with a vinyl ether of formula CHR1═CHOR2 (wherein R1 is hydrogen or alkyl and R2 is alkyl) or 3,4-dihydro-2H-pyran optionally substituted with one, two or three alkyl, in the presence of a weak acid to provide a compound of formula (4) above.


Provided in a fourth aspect is a process of synthesizing compound (1):




embedded image


wherein each R is —CH(CH2R1)—OR2 (where R1 is hydrogen or alkyl and R2 is alkyl) or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl, the process comprising:


Step (a): reacting compound (5):




embedded image


with a vinyl ether of formula CHR1═CHOR2 (wherein R1 is hydrogen or alkyl and R2 is alkyl) or 3,4-dihydro-2H-pyran optionally substituted with one, two or three alkyl, in the presence of a weak acid to provide a compound of formula (4):




embedded image


wherein each R is —CH(CH2R1)—OR2 (where R1 is hydrogen or alkyl and R2 is alkyl) or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl;


Step (b): treating compound (4) in situ with a formylating agent to provide a compound of formula (2):




embedded image


Step (c): treating the compound of formula (2) in situ with an acid to provide compound (1) above;


Step (d): optionally converting compound (1) to Compound (Ia):




embedded image


by reacting compound (1) with a compound of formula (3)




embedded image


where LG is a leaving group under alkylation reacting conditions; and


Step (e): optionally crystallizing Compound (Ia) from heptane and methyl tert-butyl ether at 40°+/−5° C. to 55+/−5° C., preferably at 45°+/−5° C. to 55+/−5° C.


Further provided herein is a process of synthesizing Compound (Ia), the process comprising performing Steps (a), (b), and (c) or (b) and (c) of the fourth aspect in sequence, including embodiments and subembodiments of aspect 4 described herein. Further provided herein is a process of synthesizing Compound (Ia), the process comprising performing Steps (a), (b), (c), and (d), or (b), (c), and (d) of the fourth aspect in sequence, including embodiments and subembodiments of aspect 4 described herein. Further provided herein is a process of synthesizing Compound (Ia), the process comprising performing Steps (a), (b), (c), (d), and (e), or (b), (c), and (d) and (e) of the fourth aspect in sequence, including embodiments and subembodiments of aspect 4 described herein. In one embodiment, the first and fourth aspects further include synthesizing compound (3) from the intermediate compound (6) as provided in the seventh aspect described herein.


Further provided herein in a fifth aspect is an intermediate of the compound of formula (4):




embedded image



where each R is tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl.


In a sixth aspect, provided is an intermediate of formula (2):




embedded image


where each R is —CH(CH2R1)—OR2 (wherein R1 is hydrogen or alkyl and R2 is alkyl) or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl.


In a seventh aspect, provided is a process of synthesizing compound (6):




embedded image


the process comprising reacting a boronic acid compound of formula:




embedded image


where R3 and R4 are independently alkyl or together form —(CR′R″)2 where R′ and R″ are independently alkyl; with




embedded image


where X is halo or triflate, in the presence of a palladium catalyst and a base in an organic/aqueous reaction mixture. Compound (6) can be used in the synthesis of Compound (3) as described herein.


The above aspects can be understood more fully by reference to the detailed description and examples below, which are intended to exemplify non-limiting embodiments.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 is a XRPD pattern for crystalline Form I of Compound (Ia).



FIG. 2 is a XRPD pattern for crystalline Form II of Compound (Ia).





DETAILED DESCRIPTION

Unless otherwise stated, the following terms as used in the specification and claims are defined for the purposes of this Application and have the following meaning:


“Alkyl” means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl, pentyl, and the like.


“Optional” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “optionally crystallizing Compound (Ia) from heptane and methyl tert-butyl ethyl” means that the crystallization may but need not be done.


“About” as used herein means that a given amount or range includes deviations in range or amount that fall within experimental error unless indicated otherwise.


“Substantially pure” as used herein in connection with the polymorphic form refers to a compound such as Compound (Ia) wherein at least 70% by weight of the compound is present as the given polymorphic form. For example, the phrase “Compound (Ia) is substantially pure Form I or II” refers to a solid state form of Compound (Ia) wherein at least 70% by weight of Compound (Ia) is in Form I or II respectively. In one embodiment, at least 80% by weight of Compound (Ia) is in Form I or II respectively. In another embodiment, at least 85% by weight of Compound (Ia) is in Form I or II respectively. In yet another embodiment, at least 90% by weight of Compound (Ia) is in Form I or II respectively. In yet another embodiment, at least 95% by weight of Compound (Ia) is in Form I or II respectively. In yet another embodiment, at least 99% by weight of Compound (Ia) is in Form I or II respectively.


EMBODIMENTS

(a) In embodiment (a), the process of the first aspect further comprises formylating a compound of formula (4):




embedded image


wherein each R is —CH(CH2R1)—OR2 wherein R1 is hydrogen or alkyl and R2 is alkyl or R is tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl to provide a compound of formula (2).




embedded image


In a first subembodiment of embodiment (a), each R is the same. In a second subembodiment, the tetrahydropyran-2-yl moiety is unsubstituted. In a third subembodiment of embodiment (a), the tetrahydropyran-2-yl moiety is substituted with one, two, or three alkyl.


(b) In embodiment (b) the process of embodiment (a) further comprises reacting compound (5):




embedded image


with a vinyl ether of formula CHR1═CHOR2, where R1 is hydrogen or alkyl and R2 is alkyl) or 3,4-dihydro-2H-pyran optionally substituted with one, two or three alkyl, in the presence of a weak acid to provide a compound of formula (4):




embedded image


wherein each R is —CH(CH2R1)—OR2 (where R1 is hydrogen or alkyl and R2 is alkyl) or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl.


In one subembodiment of embodiment (b), the 3,4-dihydro-2H-pyran moiety is unsubstituted. In another subembodiment of embodiment (b), the 3,4-dihydro-2H-pyran moiety is substituted with one, two or three alkyl.


(c) In embodiment (c), the process of the first aspect, Step (i), fourth aspect, Step (c), and embodiments (a) and (b) is wherein the acid used in the removal of R group is an organic or inorganic acid. In a first subembodiment of embodiment (c), the acid is hydrochloric acid, sulfuric acid, trifluoroacetic acid, methanesulfonic acid, or ethanesulfonic acid. In a second subembodiment of embodiment (c), the acid is hydrochloric acid. In a third subembodiment of embodiment (c), including subembodiments and embodiments contained therein, the reaction is performed at a pH of less than about: 4, 3, 2, or 1. In a fourth subembodiment of embodiment (c), including subembodiments and embodiments contained therein, the reaction is performed at a pH of about 1 to about 3. In a fifth subembodiment of embodiment (c), including subembodiments and embodiments contained therein, the reaction is performed at a pH greater than 1. In a sixth subembodiment of embodiment (c), including subembodiments and embodiments contained therein, the reaction is performed at a pH less than 1. In a seventh subembodiment of embodiment (c), including subembodiments and embodiments contained therein, the compound (2) is treated in-situ with the organic or inorganic acid to synthesize compound (1). In an eight subembodiment of embodiment (c), including subembodiments and embodiments contained therein, the reaction is carried out in an organic solvent such as tetrahydrofuran, methyl tetrahydrofuran, ethyl ether, or dioxane. In a ninth subembodiment of embodiment (c), including subembodiments and embodiments contained therein, the reaction is carried out in an organic solvent such as tetrahydrofuran. In a tenth subembodiment of embodiment (c), including subembodiments and embodiments contained therein, the reaction is carried out at temperatures less than 30° C.+/−5° C., preferably the reaction is carried out at temperatures less than about 20° C. In an eleventh subembodiment of embodiment (c), including subembodiments and embodiments contained therein, the deprotection is performed in a shorter amount of time than previous synthetic routes. The shortened deprotection time can reduce polymerization or decomposition of the intermediate compound (1) and/or, (2) as described herein.


(d) In embodiment (d), the process of the first and fourth aspects, embodiments (a), (b) and (c) and subembodiments contained therein, is wherein LG is chloro, bromo, tosylate, mesylate, or triflate. LG can preferably be chloro. In a first subembodiment of embodiment (d), LG is chloro and the reaction is carried out in the presence of a non-nucleophilic organic base (such as pyridine, trimethylamine, N-methyl-2-pyrrolidone, and diisopropylethylamine in the presence of a weak inorganic base such as sodium bicarbonate, potassium bicarbonate, cesium carbonate, and the like). In a second subembodiment of embodiment (d), the weak inorganic base is sodium bicarbonate. In a third subembodiment of embodiment (d), LG is chloro and the reaction is carried out in the presence of pyridine and a weak inorganic base such as sodium bicarbonate. In a fourth subembodiment of embodiment (d) and subembodiments and embodiments contained therein, the reaction is carried out in N-methyl-2-pyrrolidinone. In a fifth subembodiment of embodiment (d), LG is chloro and the reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and catalytic amount of NaI. In a sixth sub-embodiment of the embodiment (d) and sub-embodiments contained therein, the reaction is carried out at between 40° C. to 50° C. In a seventh sub-embodiment of the embodiment (d) and sub-embodiments contained therein, the reaction is carried out at between 43° C. to 45° C. In an eight sub-embodiment of the embodiment (d) and sub-embodiments contained therein, after the reaction is complete, the reaction mixture is treated with water and then seeded with Compound (Ia) Form I at 40° C. to 50° C., preferably 40° to 46° C. to give Compound (Ia) as substantially pure Form I, preferably Compound (Ia) is at least 95% by weight pure Form I.


(e) In embodiment (e), the process of the first aspect, Step (iii), fourth aspect Step (e) and embodiments (a), (b), (c) and (d) and subembodiments contained therein is wherein-, the crystallization of Compound (Ia) is carried out at 45+/−5° C. to 55+/−5° C. or at 45° C. to 55° C., and the solvent is n-heptane and methyl tert-butyl ether to provide substantially pure Compound (Ia) Form II. In one embodiment, at least 95% by wt of Compound (Ia) is Form II. In one embodiment, at least 98% by wt of Compound (Ia) is Form II. In one embodiment, at least 99% by wt of Compound (Ia) is Form II.


(f) In embodiment (f), the process of the first, second, third, fourth, fifth, and sixth aspects, embodiments (a)-(e), and subembodiments contained therein is wherein, each R is —CH(CH3)—O—CH2CH3, —CH(C2H5)—O—CH2CH3. In one subembodiment of (g), each R is —CH(CH3)—O—CH2CH3.


(g) In embodiment (g), the process of the first, second, third, fourth, fifth, and sixth aspects, embodiments (a)-(e), and subembodiments contained therein is wherein, each R is tetrahydropyran-2-yl optionally substituted with one or two methyl. In a first subembodiment of (g), R is tetrahydrofuran-2-yl. In a second subembodiment of (g), each R is tetrahydropyran-2-yl is substituted with one methyl.


(h) In embodiment (h), the process of the third and fourth aspects, embodiments (a)-(e), and subembodiments contained therein is wherein, the acid used in the conversion of compound (5) to the compound of formula (4) is a weak acid such as p-toluenesulfonic acid or pyridinium tosylate. In a first subembodiment of embodiment (h), the acid is pyridinium tosylate.


(i) In embodiment (i) the process of second aspect and fourth aspect, Step (b), embodiments (a)-(i) and subembodiments contained therein, is wherein the formylating agent is n-BuLi and DMF, or n-formylmorpholine. In a first subembodiment of embodiment (i), the formylating agent is n-BuLi and DMF. In a second subembodiment of embodiment (i), including the first subembodiment of embodiment (i), the reaction is carried out in THF.


(j) In embodiment (j) the process of the seventh aspect, is wherein the palladium catalyst is dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) or its dichloromethane adduct. In a first subembodiment of embodiment (j), R3 and R4 together form —C(CH3)2—C(CH3)2— and X is halo. In a second subembodiment of embodiment (j), including the first subembodiment of embodiment (j), R3 and R4 together form —C(CH3)2—C(CH3)2— and X is chloro.


(k) In embodiment (j) the intermediate of the fifth and sixth aspects is wherein each R is —CH(CH3)—O—CH2CH3.


(l) In embodiment (l) the intermediate of the fifth and sixth aspects is wherein, each R is tetrahydropyran-2-yl.


Form I of Compound (Ia) can be characterized by a XRPD pattern comprising X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.94°, 15.82°, 16.11°, 16.74°, 17.67°, 25.19°, 25.93° and 26.48°±0.2 °2θ. In one embodiment, Form I of Compound (Ia) is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 1. In another embodiment, the Form I of the free base of Compound (Ia) is characterized by a XRPD pattern comprising at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 12.94°, 15.82°, 16.11°, 16.74°, 17.67°, 25.19°, 25.93° and 26.48° (each ±0.2 °2θ). In another embodiment, the Form I of Compound (Ia) is characterized by a XRPD pattern comprising at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 12.94°, 15.82°, 16.11°, 16.74°, 17.67°, 25.19°, 25.93° and 26.48° (each ±0.2 °2θ). In another embodiment, Form I is characterized by a XRPD pattern comprising 1, 2, 3, 4, or more peaks as tabulated below in Table 1 that lists the XRPD peak positions and relative intensities of major XRPD peaks for Form I of Compound (Ia).









TABLE 1







XRPD peaks for Form I of Compound (Ia).









°2θ
d space (Å)
Intensity (%)












 5.51 ± 0.20
16.045
31.1


 5.63 ± 0.20
15.696
35.5


11.17 ± 0.20
7.923
2.05


12.94 ± 0.20
6.841
3.7


15.09 ± 0.20
5.870
9.8


15.82 ± 0.20
5.600
2.3


16.11 ± 0.20
5.500
4.0


16.74 ± 0.20
5.295
100


17.67 ± 0.20
5.018
4.01


18.81 ± 0.20
4.716
2.8


19.13 ± 0.20
4.639
0.9


19.38 ± 0.20
4.581
1.0


20.41 ± 0.20
4.350
3.4


21.00 ± 0.20
4.230
2.9


21.72 ± 0.20
4.092
2.2


22.36 ± 0.20
3.976
10.6


22.86 ± 0.20
3.890
1.7


23.30 ± 0.20
3.817
1.2


25.19 ± 0.20
3.54
7.9


25.33 ± 0.20
3.516
19.1


25.93 ± 0.20
3.436
8.7


26.48 ± 0.20
3.366
3.6


28.01 ± 0.20
3.185
24.8


28.27 ± 0.20
3.157
1.49









Form II of Compound (Ia) can be characterized by a XRPD pattern comprising a X-ray powder diffraction peak (Cu Kα radiation at one or more of 13.44°, 14.43°, 19.76°, 23.97°±0.2 °2θ. In another embodiment, Form II of Compound (Ia) is characterized by a XRPD pattern comprising a X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 2. In another embodiment, Form II of Compound (Ia) is characterized by a XRPD pattern comprising at least two X-ray powder diffraction peak (Cu Kα radiation) selected from 13.44°, 14.43°, 19.76°, 23.97 °2θ (each ±0.2 °2θ). In another embodiment, Form II of Compound (Ia) is characterized by a XRPD pattern comprising at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.44°, 14.43°, 19.76°, and 23.97 °2θ (each ±0.2 °2θ). In another embodiment, Form II of Compound (Ia) is characterized by a XRPD pattern comprising X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.44°, 14.43°, 19.76°, and 23.97 °2θ (each ±0.2 °2θ).


In another embodiment, Form II is characterized by 1, 2, 3, 4, or more peaks as tabulated below in Table 2 that lists the XRPD peak positions and relative intensities of major XRPD peaks for Form II of Compound (Ia).









TABLE 2







Major XRPD peaks for Form II of Compound (Ia).









°2θ
d space (Å)
Intensity (%)












 5.70 ± 0.20
15.494
24.8


 9.64 ± 0.20
9.172
5.4


11.32 ± 0.20
7.812
12.2


11.52 ± 0.20
7.680
12.2


12.66 ± 0.20
6.992
10.3


12.90 ± 0.20
6.861
16.4


13.44 ± 0.20
6.587
28.5


14.43 ± 0.20
6.137
28.7


14.79 ± 0.20
5.991
18.3


15.38 ± 0.20
5.761
17.5


16.18 ± 0.20
5.477
16.4


16.51 ± 0.20
5.370
72.3


17.04 ± 0.20
5.205
100


18.56 ± 0.20
4.781
71.1


20.01 ± 0.20
4.437
22.5


20.31 ± 0.20
4.373
7.7


23.06 ± 0.20
3.858
16.3


23.97 ± 0.20
3.712
19.7


24.46 ± 0.20
3.639
34.1


25.06 ± 0.20
3.554
53.6


25.45 ± 0.20
3.500
88.0


26.29 ± 0.20
3.390
23.5


26.78 ± 0.20
3.329
12.6


27.07 ± 0.20
3.294
26.2


27.49 ± 0.20
3.245
5.4


28.09 ± 0.20
3.176
15.6


28.54 ± 0.20
3.128
13.44









The processes described herein can be used for synthesizing Compound (Ia) at a manufacturing scale synthesis (e.g., at least 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 20, 25, 50, 100, or more kg amounts). The processes described herein can be useful for larger scale syntheses (e.g., at least 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 20, 25, 50, 100, or more kg amounts) which retain the physical properties, purity, efficacy, a combination thereof, or all thereof, of Compound (Ia).


The processes described herein surprisingly reduce polymerization of compound (1) and surprisingly reduce polymerization intermediates during the synthesis of Compound (Ia). In one embodiment, the polymerization can be reduced by at least 5%, 10%, 20%, 25%, 50%, 75%, 80%, 90%, 95% or more compared to previous synthesis routes as described herein.


The processes described herein surprisingly reduce decomposition reactions during the synthesis of (and deprotection of) compound (1). The decomposition reactions can be reduced by at least 5%, 10%, 20%, 25%, 50%, 75%, 80%, 90%, 95% or more compared to previous synthesis routes as described herein. The processes described herein can increase the purity of the final product of Compound (Ia) by at least 5%, 10%, 20%, 25%, 50%, 75%, 80%, 90%, 95%, 97%, 99% or more compared to previous synthesis routes as described herein.


XRPD Analysis:


XRPD patterns were collected with a PANalytical X'Pert3 X-ray Powder Diffractometer using an incident beam of Cu Kα radiation (Kα1 (Å): 1.540598, Kα2 (Å): 1.544426 Kα2/Kα1 intensity ratio: 0.50, tube setting at 45 kV, 40 mA). A continuous scan mode between 3 and 40 (°2Θ) with a scan speed of 50 s per step and a step size of 0.0263 (°2Θ) in reflection mode was used. The diffractometer was configured using the symmetric Bragg-Brentano geometry. Data collection used Data Collector Version® 4.3.0.161 and Highscore Plus® version 3.0.0.


EXAMPLES
Example 1
Synthesis of 2,6-dihydroxybenzaldehyde (Compound (1))



embedded image



Step 1:


Tetrahydrofuran (700 mL) was added to resorcinol (170 g, 1.54 mol, 1 eq.) under inert gas protection, followed by addition of pyridinium tosylate (3.9 g, 15.4 mmol, 0.01 eq.), THF 65 mL) and the reaction mixture was cooled down to 0-5° C. Within 1-1.5 h ethylvinyl ether (444 mL, 4.63 mol, 3.0 eq.) was added while maintaining a temperature ≤5° C. After the addition was complete the reaction mixture was allowed to reach room temperature within 1.5 h. The reaction was stirred overnight, cooled down to 10-15° C., and 510 mL of ½ sat. NaHCO3 was added while maintaining the reaction solution below 20° C. The phases were separated. The organic phase was washed once with 425 mL of water and once with 425 mL 12.5% NaCl solution and evaporated and azeotroped with THF to give bis-EOE-protected resorcinol (401.2 g, 1.55 mol, 102% uncorrected) as a clear colorless to yellowish oil.


Step 2:


Bis-EOE-protected resorcinol (390 g of, actual: 398.6 g=1.53 mol, 1 eq., corrected to 100% conversion) was added under inert gas protection to a 6 L glass vessel and THF (1170 mL) was added. The reaction mixture was cooled down to −10° C. to −5° C. and n-BuLi (625 mL, 2.7 M in heptane, 1.687 mol, 1.1 eq.) was added. The reaction mixture was agitated at −5° C.-0° C. for 30-40 min and then DMF (153.4 mL, 1.99 mmol, 1.3 eq.) was added starting at −10° C. to −5° C. The reaction mixture was stirred until complete and then quenched with 1N HCl/EtOAc. It was also discovered, inter alia, that protection with the EOE groups not only resulted in less byproducts but appeared to increase the speed of the formylation reaction to provide 2,6-bis(1-ethoxyethoxy)benzaldehyde (compound (2)).


The mixture was worked up, phase separated and the aqueous washed with MTBE. After aqueous wash to remove salts the organic phase was concentrated to the neat oil to obtain the compound (2) as yellow oil (almost quantitative).


A batch preparation was performed using solvent swap and was completed faster than other known methods for synthesizing Compound (Ia) with better purity and yield. The deprotection sequence allowed in-situ use of compound (2).


Step 3:


To the reaction solution of Step 2 was added 1N HCl (1755 mL) while maintaining the temperature <20° C. The pH was of the solution was adjusted to pH=0.7-0.8 with 6 M HCl. The reaction mixture was stirred for 16 h. After the reaction was complete the organic phase was separated and 1560 mL of methyl tert butyl ether was added. The organic phase was washed once with 1170 mL of 1N HCl, once with 780 mL of ½ sat. NaCl solution and once with 780 mL of water and then concentrated to a volume of ˜280 mL. To the solution was added 780 mL of methyl tert butyl ether and concentrate again to 280 mL [temperature <45° C., vacuo]. To the slurry was added 780 mL of acetonitrile and the solution was concentrated in vacuo at T<45° C. to a final volume of ˜280 mL. The slurry was heated to re-dissolve the solids. The solution was cooled slowly to RT and seeded at 60-65° C. to initiate crystallization of the product. The slurry was cooled down to −20° C. to −15° C. and agitated at this temperature for 1-2 h. The product was isolated by filtration and washed with DCM (pre-cooled to −20° C. to −15° C.) and dried under a stream of nitrogen to give 2,6-dihydroxybenzaldehyde as a yellow solid. Yield: 138.9 g (1.00 mol, 65.6%).


Example 1A
Alternate Synthesis of 2,6-dihydroxybenzaldehyde Compound (1)



embedded image



Step 1:


In a suitable reactor under nitrogen, tetrahydrofuran (207 L) was added to resorcinol (46 kg, 0.42 kmol, 1 eq.) followed by addition of pyridinium tosylate (1.05 kg, 4.2 mol, 0.01 eq.), and the reaction mixture was cooled down to 0-5° C. Within 1-1.5 h ethylvinyl ether (90.4 kg, 120.5 L, 125 kmol, 3.0 eq.) was added while maintaining a temperature ≤5° C. After the addition was complete the reaction mixture was allowed to reach room temperature within 1.5 h. The reaction was stirred overnight, cooled down to 10-15° C., and 138 L of aqueous 4% NaHCO3 was added while maintaining the reaction solution below 20° C. The phases were separated. The organic phase was washed once with 115 L of water and once with 125.2 kg of a 12.5% NaCl solution. The organic layer was dried by azeotropic distillation with THF to a water content value <0.05% (by weight) to yield bis-EOE-protected resorcinol (106.2 kg, 0.42 kmol) as a solution in THF. An advantage over previously reported protection procedures is that the bis-EOE-protected resorcinol product does not need to be isolated as a neat product. The product-containing THF solution can be used directly in the next reaction step thus increasing throughput and reducing impurity formation.


Step 2:


Bis-EOE-protected resorcinol solution (assumption is 100% conversion) was added under inert gas protection to suitable reactor. The reaction mixture was cooled down to −10° C. to −5° C. and n-BuLi (117.8 kg, 25% in heptane, 1.1 eq.) was added. The reaction mixture was agitated at −5° C.-0° C. for 30-40 min and then DMF (39.7 kg, 0.54 kmol, 1.3 eq.) was added at −10° C. to −5° C. The reaction mixture was stirred until complete and then quenched with aqueous HCl (1M, 488.8 kg) to give 2,6-bis(1-ethoxyethoxy)benzaldehyde. An advantage over previously reported procedures of using EOE protecting group is that the HCl quenched solution can be used directly in the deprotection step, and 2,6-bis(1-ethoxyethoxy)benzaldehyde does not need to be isolated as a neat oil.


Step 3:


The pH of the quenched solution was adjusted to <1 with aqueous HCl (6M, ca 95.9 kg) and the reaction mixture stirred at ambient temperature for 16 h. After the reaction was complete the organic phase was separated and 279.7 kg of methyl tert butyl ether was added. The organic phase was washed once with aqueous 1N HCl (299 kg), once with aqueous 12.5% NaCl (205.8 kg) and once with 189 kg of water and then concentrated to a volume of ca. 69 L. To the slurry was added 164 kg of acetonitrile and the solution was concentrated in vacuo at T<45° C. to a final volume of ca. 69 L. The slurry was heated to re-dissolve the solids. The solution was seeded at 60-65° C. to initiate crystallization of the product and cooled slowly to RT over 8 hrs. The slurry was cooled down to −20° C. to −15° C. and agitated at this temperature for 1-2 h. The product was isolated by filtration and washed with DCM (50.3 kg, pre-cooled to −20° C. to −15° C.) and dried under a stream of nitrogen to yield 2,6-dihydroxybenzaldehyde as a yellow solid. Yield: 37.8 kg (0.27 kmol, 65.4% Yield). The described telescoped approach from deprotection to crystallization increases the throughput and integrity of the product.


Example 2
Synthesis of 3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine dihydrochloride salt



embedded image



Step 1:


An appropriately sized flask was purged with nitrogen and charged with (2-chloropyridin-3-yl)methanol (1.0 equiv), sodium bicarbonate (3.0 equiv), [1, 1′-bis(diphenyl-phosphino)-ferrocene]dichloropalladium (5 mol %), 1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.2 equiv), and a mixture of 2-MeTHF (17.4 vol) and deionized water (5.2 vol). The resulting solution was heated to 70° C. to 75° C. and conversion monitored by HPLC. Once the reaction was complete, the reaction mixture was cooled to room temperature, diluted with deionized water, and the phases were separated. The organic layer was extracted with 2 N HCl (10 vol) and the phases were separated. The aqueous phase was washed with MTBE. The pH of the aqueous phase was adjusted to 8-9 with 6 N NaOH. The product was extracted into EtOAc, treated with Darco G-60 for 30 to 60 min, dried over MgSO4, filtered through Celite®, and concentrated to give (2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methanol as a brown oil.


Step 2:


A suitably equipped reactor was charged with (2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methanol hydrochloride salt (1 equivalent) and purified water. An aqueous sodium bicarbonate solution (8% NaHCO3) was added slowly to maintain the solution temperature between 17° C. to 25° C. After addition was complete, the reaction mixture was stirred at 17° C. to 25° C. and dichloromethane was added and the organic layer was separated. DCM solution was then distilled under atmospheric conditions at approximately 40° C. and the volume was reduced. DCM was added the reactor and the contents of the reactor are stirred at 20° C. to 30° C. until a clear solution is formed. The contents of the reactor were cooled to 0° C. to 5° C. and thionyl chloride was charged to the reactor slowly to maintain a temperature of ≤5° C. The reaction solution was stirred at 17° C. to 25° C. When the reaction was complete, a solution of HCl (g) in 1,4-dioxane (ca. 4 N, 0.8 equiv.) was charged to the reactor slowly to maintain the solution temperature between 17° C. and 25° C. The product 3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine dihydrochloride salt was filtered washed with dichloromethane and dried.


Example 3
Synthesis of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (Compound (Ia)) Form I



embedded image


A suitably equipped reactor was charged with 3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine dihydrochloride salt (1 equivalent), sodium iodide (0.05 equivalent), sodium bicarbonate (4 equivalent), 1-methyl-2-pyrrolidinone (NMP), and 2,6-dihydroxy-benzaldehyde (1 to 1.05 equiv.). The reaction mixture was heated slowly to 40° C. to 50° C. and stirred until the reaction was complete. Water was then added and the reaction mixture was cooled and maintained at 17° C. to 25° C. When the water addition was complete, the reaction mixture was stirred at 17° C. to 25° C. and slowly cooled to 0° C. to 5° C. and the resulting solids were collected by filtration. The solids were washed with a 0° C. to 5° C. 2:1 water/NMP solution, followed by 0° C. to 5° C. water. The solids were filtered and dried to give 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde as Form I or a mixture of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde as Form I and NMP solvates.


Alternative Synthesis:


A suitably equipped reactor was charged with 3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine bishydrochloride salt (1 equivalent), sodium iodide (0.05 equivalent), sodium bicarbonate (3 to 4 equivalent), 1-methyl-2-pyrrolidinone (7 equivalent, NMP), and 2,6-dihydoxybenzaldehyde (1.05 equivalent). The reaction mixture was heated to 40° C. to 50° C. and stirred until the reaction was complete. Water (5 equivalent) was then added while maintaining the contents of the reactor at 40° C. to 46° C. and the resulting clear solution seeded with 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde Form I. Additional water (5 equivalent) was added while maintaining the contents of the reactor at 40° C. to 50° C., the reactor contents cooled to 15° C. to 25° C., and the reactor contents stirred for at least 1 hour at 15° C. to 25° C. The solids were collected, washed twice with 1:2 NMP:water and twice with water, and dried to yield 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde Form I devoid of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde as NMP solvates.


Example 4
Preparation of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)-benzaldehyde (Compound (Ia)) Form II



embedded image



Step 1:


A suitably equipped reactor with an inert atmosphere was charged with crude 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (from Example 3 above) and MTBE and the contents stirred at 17° C. to 25° C. until dissolution was achieved. The reaction solution was passed through a 0.45 micron filter and MTBE solvent volume reduced using vacuum distillation at approximately 50° C. The concentrated solution was heated to 55° C. to 60° C. to dissolve any crystallized product. When a clear solution was obtained, the solution was cooled to 50° C. to 55° C. and n-heptane was added. 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (e.g., Form II) seeds in a slurry of n-heptane were charged and the solution was stirred at 50° C. to 55° C. The solution was cooled to 45° C. to 50° C. and n-heptane was added to the reactor slowly while maintaining a reaction solution temperature of 45° C. to 50° C. The reaction solution are stirred at 45° C. to 50° C. and then slowly cooled to 17° C. to 25° C. A sample was taken for FTIR analysis and the crystallization was considered complete when FTIR analysis confirmed 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)-benzaldehyde Form II. The contents of the reactor were then cooled to 0° C. to 5° C. and the solids were isolated and washed with cold n-heptane and dried.

Claims
  • 1. A compound of formula (2):
  • 2. The compound of claim 1, wherein each R is independently —CH(CH3)—O—CH2CH3 or —CH(CH2CH3)—O—CH2CH3.
  • 3. The compound of claim 1, wherein each R is —CH(CH3)—O—CH2CH3.
  • 4. The compound of claim 1, wherein each R is —CH(CH2CH3)—O—CH2CH3.
  • 5. A method of preparing the compound of formula (2):
  • 6. The method of claim 5, wherein the formylating agent is n-butyllithium (n-BuLi) and dimethylformamide (DMF).
  • 7. The method of claim 5, wherein the formylating agent is N-formylmorpholine.
  • 8. The method of claim 5, further comprising reacting compound (5):
  • 9. The method of claim 8, wherein the formylating agent is n-butyllithium and dimethylformamide.
  • 10. The method of claim 8, wherein the formylating agent is N-formylmorpholine.
  • 11. A compound of formula (2a):
  • 12. A method of preparing a compound of formula (2a)
  • 13. The method of claim 12, wherein the formylating agent is n-butyllithium and dimethylformamide.
  • 14. The method of claim 12, wherein the formylating agent is N-formylmorpholine.
  • 15. The method of claim 12, further comprising reacting compound (5):
  • 16. The method of claim 15, wherein the formylating agent is n-butyllithium and dimethylformamide.
  • 17. The method of claim 15, wherein the formylating agent is N-formylmorpholine.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/593,198, filed May 11, 2017, now U.S. Pat. No. 10,077,249, which application claims priority to U.S. Provisional Patent Application No. 62/335,583, filed May 12, 2016, each of which is incorporated herein by reference in its entirety and for all purposes.

US Referenced Citations (135)
Number Name Date Kind
3236893 Blout et al. Feb 1966 A
4062858 Hoehn et al. Dec 1977 A
4410537 Kneen Oct 1983 A
4478834 Shroff et al. Oct 1984 A
4535183 Kneen Aug 1985 A
5185251 Chen et al. Feb 1993 A
5202243 Balani Apr 1993 A
5266582 De Nanteuil et al. Nov 1993 A
5290941 Volante et al. Mar 1994 A
5403816 Takabe et al. Apr 1995 A
5521202 Yano et al. May 1996 A
5679678 Binder et al. Oct 1997 A
5681567 Martinez et al. Oct 1997 A
5760232 Chen et al. Jun 1998 A
5840900 Greenwald et al. Nov 1998 A
5880131 Greenwald et al. Mar 1999 A
5965566 Greenwald et al. Oct 1999 A
5994353 Breault Nov 1999 A
6011042 Greenwald et al. Jan 2000 A
6111107 Greenwald et al. Aug 2000 A
6127355 Greenwald et al. Oct 2000 A
6153655 Martinez et al. Oct 2000 A
6194580 Greenwald et al. Feb 2001 B1
6214817 Riley et al. Apr 2001 B1
6232320 Stewart et al. May 2001 B1
6239176 Nudelman et al. May 2001 B1
6242644 Ackermann et al. Jun 2001 B1
6355661 Lai et al. Mar 2002 B1
6395266 Martinez et al. May 2002 B1
6472349 Hamprecht et al. Oct 2002 B1
6593472 Hoffman et al. Jul 2003 B2
6608076 Greenwald et al. Aug 2003 B1
6627646 Bakale Sep 2003 B2
6630496 Seehra et al. Oct 2003 B1
6670377 Mekouar et al. Dec 2003 B1
7160910 Safo et al. Jan 2007 B2
7411083 Gopalsamy et al. Aug 2008 B2
8846694 Heinrich et al. Sep 2014 B2
8952171 Xu et al. Feb 2015 B2
9012450 Metcalf et al. Apr 2015 B2
9018210 Metcalf et al. Apr 2015 B2
9150569 Fukuda et al. Oct 2015 B2
9248199 Metcalf et al. Feb 2016 B2
9422279 Metcalf et al. Aug 2016 B2
9447071 Li et al. Sep 2016 B2
9458139 Xu et al. Oct 2016 B2
9604999 Harris et al. Mar 2017 B2
9776960 Xu et al. Oct 2017 B2
9802900 Li et al. Oct 2017 B2
10017491 Metcalf et al. Jul 2018 B2
10034879 Metcalf et al. Jul 2018 B2
10137118 Li et al. Nov 2018 B2
20010046997 Abraham et al. Nov 2001 A1
20020095035 Warshawsky et al. Jul 2002 A1
20020142995 Nicolau et al. Oct 2002 A1
20020147138 Firestone et al. Oct 2002 A1
20030022923 Lai et al. Jan 2003 A1
20030060425 Ahlem et al. Mar 2003 A1
20030073712 Wang et al. Apr 2003 A1
20030165714 Lee et al. Sep 2003 A1
20030187026 Li et al. Oct 2003 A1
20030190333 Mossman et al. Oct 2003 A1
20030199511 Li et al. Oct 2003 A1
20040072796 Embury et al. Apr 2004 A1
20040186077 Diakur et al. Sep 2004 A1
20040209921 Bridger et al. Oct 2004 A1
20050085484 Mitchell et al. Apr 2005 A1
20050096337 Ackermann et al. May 2005 A1
20050143420 Moutouh-De Parseval et al. Jun 2005 A1
20050159605 Tarur et al. Jul 2005 A1
20060094761 Haque et al. May 2006 A1
20070213323 Imogai et al. Sep 2007 A1
20070293698 Quick et al. Dec 2007 A1
20080114167 Castro et al. May 2008 A1
20090023709 Gillespie et al. Jan 2009 A1
20090143371 Buettelmann Jun 2009 A1
20090163512 Chen et al. Jun 2009 A1
20090312315 Yamaguchi et al. Dec 2009 A1
20100048901 Takahashi et al. Feb 2010 A1
20100204235 Lizos et al. Aug 2010 A1
20100210651 Hernandez et al. Aug 2010 A1
20100311748 Dakin et al. Dec 2010 A1
20120220569 Ohashi et al. Aug 2012 A1
20120245344 Endo et al. Sep 2012 A1
20130045251 Cen et al. Feb 2013 A1
20130072472 Gless et al. Mar 2013 A1
20130190315 Metcalf et al. Jul 2013 A1
20130190316 Metcalf et al. Jul 2013 A1
20130190375 Dunkel et al. Jul 2013 A1
20130273157 Ishii et al. Oct 2013 A1
20140004184 Ashraf et al. Jan 2014 A1
20140142149 Zhang et al. May 2014 A1
20140271591 Sinha et al. Sep 2014 A1
20140274961 Metcalf et al. Sep 2014 A1
20140275152 Metcalf et al. Sep 2014 A1
20140275176 Xu et al. Sep 2014 A1
20140275181 Harris et al. Sep 2014 A1
20150057251 Harris Feb 2015 A1
20150133430 Xu et al. May 2015 A1
20150141465 Yee et al. May 2015 A1
20150225366 Li Aug 2015 A1
20150259296 Li et al. Sep 2015 A1
20150336908 Shioda et al. Nov 2015 A1
20150344472 Metcalf et al. Dec 2015 A1
20150344483 Metcalf et al. Dec 2015 A1
20160024127 Harris et al. Jan 2016 A1
20160031865 Li et al. Feb 2016 A1
20160031904 Li et al. Feb 2016 A1
20160038474 Sinha et al. Feb 2016 A1
20160039801 Metcalf et al. Feb 2016 A1
20160046613 Metcalf et al. Feb 2016 A1
20160083343 Xu et al. Mar 2016 A1
20160303099 Dufu et al. Mar 2016 A1
20160152602 Xu et al. Jun 2016 A1
20160206604 Metcalf et al. Jul 2016 A1
20160206614 Metcalf et al. Jul 2016 A1
20160207904 Li et al. Jul 2016 A1
20160332984 Metcalf et al. Nov 2016 A1
20160346263 Li et al. Dec 2016 A1
20170107199 Metcalf et al. Apr 2017 A1
20170157101 Ramos et al. Jun 2017 A1
20170174654 Metcalf et al. Jun 2017 A1
20170355713 Harris et al. Dec 2017 A1
20180125789 Dalziel et al. May 2018 A1
20180186807 Yee et al. Jul 2018 A1
20180201577 Xu et al. Jul 2018 A1
20180354929 Metcalf et al. Dec 2018 A1
20190010121 Xu et al. Jan 2019 A1
20190010176 Harris Jan 2019 A1
20190106404 Li et al. Apr 2019 A1
20190111037 Li et al. Apr 2019 A1
20190112287 Metcalf et al. Apr 2019 A1
20190160060 Metcalf et al. May 2019 A1
20190202782 Xu et al. Jul 2019 A1
20190255031 Li et al. Aug 2019 A1
Foreign Referenced Citations (179)
Number Date Country
2720096 Oct 2009 CA
101113148 Jan 2008 CN
102116772 Jul 2011 CN
2238734 Feb 1973 DE
2238628 Mar 1973 DE
2853765 Jun 1980 DE
2904829 Aug 1980 DE
226590 Aug 1985 DE
3503435 Aug 1985 DE
3431004 Mar 1986 DE
3704223 Aug 1987 DE
258226 Jul 1988 DE
276479 Feb 1990 DE
276480 Feb 1990 DE
3931954 Mar 1990 DE
4318550 Dec 1994 DE
4442050 May 1996 DE
010063 Apr 1980 EP
0054924 Jun 1982 EP
236140 Sep 1987 EP
0268989 Jun 1988 EP
0278686 Aug 1988 EP
0291916 Nov 1988 EP
0303465 Feb 1989 EP
0336369 Oct 1989 EP
0348155 Dec 1989 EP
0365328 Apr 1990 EP
0401517 Dec 1990 EP
0453210 Oct 1991 EP
0462800 Dec 1991 EP
0481802 Apr 1992 EP
0498380 Aug 1992 EP
0528337 Feb 1993 EP
0542372 May 1993 EP
0567133 Oct 1993 EP
0632036 Jan 1995 EP
0637586 Feb 1995 EP
0640609 Mar 1995 EP
0747393 Dec 1996 EP
2123637 Nov 2009 EP
2149545 Mar 2010 EP
2305625 Jun 2011 EP
2217016 Jan 1900 FR
2909379 Jun 2008 FR
1409865 Oct 1975 GB
1593417 Jul 1981 GB
64573 Apr 1985 IL
57-145844 Jun 1905 JP
59029667 Feb 1984 JP
61-040236 Feb 1986 JP
63230687 Sep 1988 JP
S-63258463 Oct 1988 JP
01190688 Jul 1989 JP
06-041118 Feb 1994 JP
07-025882 Jan 1995 JP
2002-523469 Jul 2002 JP
2002-528537 Sep 2002 JP
2003-075970 Mar 2003 JP
2003-513060 Apr 2003 JP
2006-342115 Dec 2006 JP
2008-137914 Jun 2008 JP
2009-203230 Sep 2009 JP
WO-9119697 Dec 1991 WO
WO-9202503 Feb 1992 WO
WO-9317013 Sep 1993 WO
WO-9401406 Jan 1994 WO
WO-9514015 May 1995 WO
WO-9521854 Aug 1995 WO
WO-9611902 Apr 1996 WO
WO-9741120 Nov 1997 WO
WO-9744306 Nov 1997 WO
WO-9808818 Mar 1998 WO
WO-9821199 May 1998 WO
WO-9929694 Jun 1999 WO
WO-9943672 Sep 1999 WO
WO-9947529 Sep 1999 WO
WO-9948490 Sep 1999 WO
WO-9959978 Nov 1999 WO
WO-9962908 Dec 1999 WO
WO-0012121 Mar 2000 WO
WO-0026202 May 2000 WO
WO-0035858 Jun 2000 WO
WO-0040564 Jul 2000 WO
WO-0071123 Nov 2000 WO
WO-0075145 Dec 2000 WO
WO-0078746 Dec 2000 WO
WO-0100612 Jan 2001 WO
WO-0119823 Mar 2001 WO
WO-0123383 Apr 2001 WO
WO-0132596 May 2001 WO
WO-0136375 May 2001 WO
WO-0157006 Aug 2001 WO
WO-0157044 Aug 2001 WO
WO-0162705 Aug 2001 WO
WO-0170663 Sep 2001 WO
WO-0200622 Jan 2002 WO
WO-0212235 Feb 2002 WO
WO-0224635 Mar 2002 WO
WO-0224679 Mar 2002 WO
WO-02051849 Jul 2002 WO
WO-02053547 Jul 2002 WO
WO-02061849 Aug 2002 WO
WO-03051366 Jun 2003 WO
WO-03053368 Jul 2003 WO
WO-03101959 Dec 2003 WO
WO-2004014899 Feb 2004 WO
WO-2004018430 Mar 2004 WO
WO-2004024705 Mar 2004 WO
WO-2004050030 Jun 2004 WO
WO-2004056727 Jul 2004 WO
WO-2004058790 Jul 2004 WO
WO 2004073675 Sep 2004 WO
WO-2004087075 Oct 2004 WO
WO-2004111031 Dec 2004 WO
WO-2005047249 May 2005 WO
WO-2005074513 Aug 2005 WO
WO-2005077932 Aug 2005 WO
WO-2005086951 Sep 2005 WO
WO-2005087766 Sep 2005 WO
WO-2005096337 Oct 2005 WO
WO-2006011469 Feb 2006 WO
WO-2006065204 Jun 2006 WO
WO-2006088173 Aug 2006 WO
WO-2006103463 Oct 2006 WO
WO-2006106711 Oct 2006 WO
WO-2006116764 Nov 2006 WO
WO-2006003923 Dec 2006 WO
WO-2007003962 Jan 2007 WO
WO-2007009389 Jan 2007 WO
WO-2007017267 Feb 2007 WO
WO-2007047204 Apr 2007 WO
WO-2007049675 May 2007 WO
WO-2007061923 May 2007 WO
WO-2007084914 Jul 2007 WO
WO-2007117180 Oct 2007 WO
WO 2008012495 Jan 2008 WO
WO-2008013414 Jan 2008 WO
WO-2008016132 Feb 2008 WO
WO-2008029200 Mar 2008 WO
WO-2008041118 Apr 2008 WO
WO-2008051532 May 2008 WO
WO-2008060391 May 2008 WO
WO-2008066145 Jun 2008 WO
WO-2008081096 Jul 2008 WO
WO-2008101682 Aug 2008 WO
WO-2008116620 Oct 2008 WO
WO-2009001214 Dec 2008 WO
WO-2009011850 Jan 2009 WO
WO-2009050183 Apr 2009 WO
WO-2009125606 Oct 2009 WO
WO-2009128537 Oct 2009 WO
WO-2009130560 Oct 2009 WO
WO-2009136889 Nov 2009 WO
WO-2009146555 Dec 2009 WO
WO 2009153191 Dec 2009 WO
WO-2010031589 Mar 2010 WO
WO-2010056631 May 2010 WO
WO-2010129055 Nov 2010 WO
WO-2011033045 Mar 2011 WO
WO-2011088201 Jul 2011 WO
WO-2011136459 Nov 2011 WO
WO-2012020060 Feb 2012 WO
WO-2012138981 Oct 2012 WO
WO-2012141228 Oct 2012 WO
WO-2013052803 Apr 2013 WO
WO-2013102142 Jul 2013 WO
WO-2013102145 Jul 2013 WO
WO-2014104384 Jul 2014 WO
WO-2014150256 Sep 2014 WO
WO-2014150258 Sep 2014 WO
WO-2014150261 Sep 2014 WO
WO-2014150268 Sep 2014 WO
WO-2014150276 Sep 2014 WO
WO-2014150289 Sep 2014 WO
WO-2015031284 Mar 2015 WO
WO-2015031285 Mar 2015 WO
WO-2015120133 Aug 2015 WO
WO-2016160755 Oct 2016 WO
WO-2017096230 Jun 2017 WO
Non-Patent Literature Citations (243)
Entry
U.S. Appl. No. 61/581,053, filed Dec. 28, 2011, Metcalf et al.
U.S. Appl. No. 61/661,320, filed Jun. 18, 2012, Metcalf et al.
Abdulmalik et al., “Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin”, Acta Cryst. 2011, D67, 920-928.
Abdulmalik et al., Sickle cell disease: current therapeutic approaches, Expert Opinion Ther. Patents, 2005, vol. 15(11), pp. 1497-1506.
Abraham et al., Vanillin, a Potential Agent for the Treatment of Sickle Cell Anemia, Blood, Mar. 1991, vol. 77 (6), pp. 1334-1341.
Adhikary, P.K., et al., “A new antisickling agent: In vitro studies of its effect on S/S erythrocytes and on hemoglobin S”, Experientia. 1978, vol. 34, No. 6, pp. 804-806.
Appendix A provided with Israel office action dated Aug. 11, 2016 for IL 233329.
Arya R, et al. “Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia,” Br. J. Haematol., 93(4):817-21 (1996).
Australian Examination Report dated Nov. 7, 2016 for AU 2016203755.
Babu, et al. Regioselective synthesis and structural elucidation of 1,4-disubstituted 1,2,3-triazole derivatives using 1D and 2D NMR spectral techniques. Magn. Reson. Chem., 2011; 49: 824-829. doi:10.1002/mrc.2820.
Bacsa et al., “Novel products from Baylis-Hillman reactions of salicylaldehydes”, South African Journal of Chemistry (1998), 51(1), 47-54 CODEN: SAJCDG; ISSN: 0379-4350.
Ballerini et al., High pressure Diels-Alder approach to hydroxy-substituted 6a-cyano-tetrahydro-6H-benzo[c]chromen-6-ones: A route to Δ6-Cis-Cannabidiol. J.Org.Chem., 74(11):4311-4317, 2009.
Ballet et al., Novel selective human melanocortin-3 receptor ligands: Use of the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3- one (Aba) scaffold, Bioorganic & Medicinal Chemistry Letters (2007), 17(9), 2492-2498 CODEN: BMCLES; ISSN: 0960-894X.
Barnes, et al., “Prospects for new drugs for chronic obstructive pulmonary disease.” The Lancet, 2004, 364, 985-996.
Barnes. “COPD: is there light at the end of the tunnel?” Current Opinion in Pharmacology, 2004, 4:263-272.
Baxter et al., “Reductive aminations of carbonyl compounds with borohydride and borane reducing agents”, Organic Reactions (Hoboken, NJ, United States) (2002), 59, No pp. given bin/mrwhome/107610747/HOME.
Beaumont et al., Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr. Drug Metab. 2003, 4:461-85.
Beddell, Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocycles, Br. J. Pharmac., 82:397-407, 1984.
Beena et al., “Synthesis and antibacterial activity evaluation of metronidazole-triazole conjugates”, Bioorganic & Medicinal Chemistry Letters, 2009, 19(5):1396-1398.
Behanna. Equity Research—Global Blood Therapeutics. Sep. 8, 2015. Retrieved from the Internet: URL:http://www.fintechsecurities.com/Websites/fintechsecurities/images/Research_Blog/Zacks/Sep2015/GBT150908.pdf.
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66:1-19.
Bernstein. Crystals in Supramolecular Chemistry. ACA Transactions. 2004; 39:1-14.
Bernstein. Polymorphism in Molecular Crystals. Clarendon Press, Oxford. 2002. 115-118, 272.
Bode et al.,“Novel synthesis and x-ray crystal structure of a coumarin derivative”, South African Journal of Chemistry (1992), 45(1), 25-7 CODEN: SAJCDG; ISSN:0379-4350.
Bonaventura, et al., “Molecular Controls of the Oxygenation and Redox Reactions of Hemoglobin.” Antioxidants & Redox Signaling, 18(17), 2013, 2298-2313.
Bottino, et al. Study on the scope of tert-amino effect: new extensions of type 2 reactions to bridged biaryls. J. Phys. Org. Chem. 2012; 25(11):1033-1041.
Bradbury et al., “New nonpeptide angiotensin II receptor antagonists”, Journal of Medicinal Chemistry, 1993, vol. 36, pp. 1245-1254.
Braga, et al. Making crystals from crystals: a green route to crystal engineering and polymorphism. Chem Commun (Camb). Aug. 7, 2005;(29):3635-45. Epub Jun. 15, 2005.
Britton et al., “Structure-activity relationships of a series of benzothlophens-derived NPY Y1 antagonists: optimization of the C-2 side chain”. Bioorganic & Medicinal Chemistry Letters (1999), 9(3), 475-480 CODEN:BMCLE8;ISSN: 0960-894X.
Brown et al., “1,2-Dihydroisoquinollnes. III, Dimerization”, Tetrahedron (1966), 22(8), 2437-43 CODEN: TETRAB; ISSN;0040-4020.
Caira. Crystalline Polymorphism of Organic Compounds. Topics in Current Chemistry, Springer, Berlin, DE. 1998; 198:163-208.
CAS Registry No. 1039841-20-7; entry dated Aug. 10, 2008.
CAS Registry No. 1096911-11-3; entry dated Jan. 28, 2009.
CAS Registry No. 1153166-41-6; entry dated Jun. 7, 2009.
CAS Registry No. 1153961-01-3; entry dated Jun. 8, 2009.
CAS Registry No. 1184809-65-1; entry dated Sep. 15, 2009.
CAS Registry No. 1303782-57-1; entry dated Jun. 1, 2011.
CAS Registry No. 1306264-96-9; entry dated Jun. 5, 2011.
CAS Registry No. 631858-40-7; entry dated Dec. 29, 2003.
Chemical Abstract Registry No. 1142191-55-6, indexed in the Registry File on STN CA Online May 4, 2009.
Cheng, et al. Vilsmeier formylation of tert-anilines: dibenzo[b,f][1,5]diazocines and quinazolinium salts via the ‘t-amino effect’. J. Chem. Soc., Perkin Trans 1. 1998; 1257-1262.
Cherian et al., “Structure-Activity Relationships of Antitubercular Nitroimidazoles 3. Exploration of the Linker and Lipophilic Tail of ((S)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-13][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-Amino PA-824).,” J. Med. Chem., Aug. 2011, vol. 54(16), pp. 5639-5659.
Ciganek, “The catalyzed a-hydroxyalkylation and a-aminoalkylation of activated olefins (the Morita-Baylis-Hillman reaction”, Organic Reactions (Hoboken, NJ, United States) (1997), 51, No pp given CODEN:ORHNBA URL:http://www3.Interscience.wiley.com/cgi-bin/mnwhome/107610747/HOME.
CMU Pharmaceutical polymorphism, internet p. 1-3 (2002) printout Apr. 3, 2008.
Concise Encyclopedia Chemistry, NY: Walter de Gruyter, 1993, 872-873.
Congreve et al. Application of Fragment Screening by X-ray Crystallography to the Discovery of Aminopyridines as Inhibitors of Beta-Secretase. J. Med. Chem. 50:1124-1132 (2007).
Cos et al., “Structure-Activity Relationship and Classification of Flavonoids as Inhibitors of Xanthine Oxidase and Superoxide Scavengers,” J. Nat. Prod., (1998), 61:71-76.
Database CA Chemical Abstract Service, Li et al., “Substituted-benzoheterocycle derivatives, preparation, and application for preparation of antiviral or antineoplastic drugs,” XP002726578 retrieved from STN Database accession No. 2013:366779 (abstract); RN:1427163-92-5 & CN 102 952 062 A, Mar. 6, 2013, 2 pages.
Database Pubchem Compound Dec. 4, 2011 XP 003033770 (11 pages).
Database Registry, 2011, RN 1289869-72-2, 1027970-95-1, 959671-57-9.
Database Registry, 2012, RN 1390863-18-9, 1390573-58-6, 1389652-57-6, 1387166-17-7, 1318517-26-8, 1318395-05-9, 933829-46-0, 879919-21-8.
Davidovich, et al. Detection of polymorphism by powder x-ray diffraction: interference by preferred orientation. Am. Pharm. Rev. 2004; 10, 12, 14, 16, 100.
Dean. Analytical Chemistry Handbook. University of Tennesse, Knoxville. McGraw-Hill, Inc. 1995; 10.24-10.26.
Deem. “Red Blood Cells and Hemoglobin in Hypoxic Pulmonary Vasoconstriction” Advances in experimental medicine and biology, (2006) 588, 217-231.
Desai et al. Preparation of N-[ro-(4-aryl-1-piperazinyl)ethyl/propyl]-3-hydroxyphthalimidines. Indian Journal of Chemistry. 39:455-457 (2000).
Desideri et al., “Guanylhydrazones of 3-substituted 2-pyridinecarboxaldehyde and of (2-substituted 3-pyridinyloxy) acetaldehyde as prostanoid biosynthesis and platelet aggregation inhibitors”, European Journal of Medicinal Chemistry, Editions Scientifique Elsevier, Paris, FR, 1991, vol. 26, No. 4, pp. 455-460.
Di Stilo, et al. New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. J. Med. Chem. 41:5393-5401 (1998).
Ding et al., “Crystal structure of bis[μ2-2-(2-formylphenoxy)acetato- O,O]-bis[μ2-2-2-formylphynoxy)acetato-O,O]- octakis(n-butyl)tetratin(IV), Sn4O2(C9H7O4)4(C4H9)8”, Zeitschrift fuer Kristallographie—New Crystal Structures (2011), 226(1), 31-32 CODEN:ZKNSFT; ISSN: 1433-7266.
Doelker, English translation of S.T.P, Pratiques (1999), 9(5), 399-409.
Doelker. English translation of Ann. Pharm. Fr., 2002, 60: 161-176.
Einfalt, et al. Methods of amorphization and investigation of the amorphous state. Acta Pharm. 2013; 63:305-334.
Elwahy, “Synthesis of new benzo-substituted macrocyclic containing quinoxaline subunits” Tetrahedron (2000), 56(6), 897-907 CODEN:TETRAB; ISSN:0040-4020.
Epsztajn et al., “Application of organolithium”, Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, 1991, vol. 47, No. 9, pp. 1697-1706.
European Search Report and Search Opinion dated Aug. 4, 2015 for EP Application No. 12862525.8. 9 pages.
European Search Report and Search Opinion dated Jul. 21, 2016 for EP Application No. 14769616.5. 8 pages.
European Search Report and Search Opinion dated May 28, 2015 for EP Application No. 12862096.0. 13 pages.
European Search Report and Search Opinion dated Nov. 16, 2016 for EP Application No. 16194019.2. 13 pages.
European Search Report and Search Opinion dated Sep. 26, 2016 for EP Application No. 14768759.4. 6 pages.
Extended European Search Report and opinion dated Jul. 20, 2016 for EP Application No. 14768414.6. 10 pages.
Extended European Search Report and Search Opinion dated Jul. 18, 2016 for EP Application No. 14770695.6. 13 pages.
Extended European Search Report and Search Opinion dated Jul. 7, 2016 for EP Application No. 14768317.1.7 pages.
Extended European Search Report and Search Opinion dated May 17, 2017 for EP Application No. 15746995.8. 8 pages.
Extended European Search Report and Search Opinion dated Nov. 23, 2015 for EP Application No. 12862525.8. 16 pages.
Gadaginamath, et al., “Synthesis and antibacterial activity of novel 1-butyl-2-phenoxyl2-phenylthlol2-aminomethyl-5- methoxyindole derivatives”, Polish Journal of Chemistry (1997), 71(7), 923-928 CODEN: PJCHDQ; ISSN:0137-5083.
Gao et al, “A novel one-pot three-step synthesis of 2-(1-benzofuran-2-yl)quinoline-3-carboxylic acid derivatives”, Journal of the Brazilian Chemical Society (2010), 21(5). 806-812 CODEN:JOCSET; ISSN: 0103-5053.
Ghate et al., “Synthesis of vanillin ethers from 4-(bromomethyl) coumarins as anti-inflammatory agents, ”European Journal of Medicinal Chemistry (2003), 38(3), 297-302 CODEN: EJMCA5; ISSN: 0223-5234.
Gibson et al., “Novel small molecule bradykinin B2 receptor antagonists”, Journal of Medicinal Chemistry, 2009, vol. 52, pp. 4370-4379.
Glasson et al. Metal Template Synthesis of a Tripodal Tris(bipyridyl) Receptor that Encapsulates a Proton and an Iron (ii) Centre in a Pseudo Cage. Aust. J. Chem. 65:1371-1376 (2012).
Grashey, “The nitro group as a 1,3-dipole in cycloadditions” Angewandte Chemie (1962), 74, 155 CODEN: ANCEAD; ISSN: 0044-8249.
Guillaumel, et al. Synthetic routes to 2-(2-benzofuranyl)benzoic acids and their cyclization into benz[6]indeno[2,1-d]furan-10-ones. Journal of Heterocyclic Chemistry, 1990; 27: 1047-1051. doi:10.1002/jhet.5570270444.
Guillory (in Brittain ed.) Polymorphism in Pharmaceutical Solids. NY, Marcel Dekker, Inc. 1999; 1-2:183-226.
Gunter et al., “Structural control of co-receptor binding in porphyrin-bipyridinium supramolecular assemblies”, Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1998), (12), 1945-1958 CODEN: JCPRB4; ISSN: 0300-922X.
Hang, Song. “Pharmaceutical Separation Engineering” East China University of Technology Press. Aug. 31, 2011; 270-272. (in Chinese with English abstract).
Hanmantgad et al., “Synthesis and pharmacological properties of some r-(2-benzo[b]furanyl)coumarins” Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1986), 25B(7), 779-81 CODEN: IJSBDB; ISSN: 0376-4699.
He et al., “Prodrugs of Phosphonates, Phosphinates, and Phosphates”, Prodrugs: Challenges and rewards Part 2, edited by Stella et al., 2007, pp. 223-264.
Heimbach et al., “Enzyme-mediated precipitation of patent drugs from their phosphate prodrugs”, International Journal of Pharmaceutics, 261, p. 81-92, 2003.
Heimbach et al., “Prodrugs: Challenges and Rewards Part I,” New York, NY, Singer:AAPS Press, (2007), 5(Chapter 2.2.1):157-215 Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery.
Heimgartner et al., “Stereoselective synthesis of swainsonines from pyridines”, Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, 2005, vol. 61, No. 3, pp. 643-655.
Hoffman, et al. 3-Hydroxy-3-methyglutaryl-coenzyme A Reductase Inhibitors, 2. Structural Modification of 7-(Substituted aryl)-3,5-dihydroxy-6-heptenoic Acids and Their Lactone Derivatives. Journal of Medical Chemistry. 29(2):159-169 (1986).
Hong et al., “Potential Anticancer Agents VI: 5-Substituted Pyrimidine-6-Carboxaldehydes”, Journal of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, US, 1970, vol. 59, No. 11, pp. 1637-1645.
Huckauf, et al., “Oxygen Affinity of Haemoglobin and Red Cell Acid-Base Status in Patients with Severe Chronic Obstructive Lung Disease” Bull. Europe Physiopath. Resp., 1976, 12, 129-142.
International Preliminary Report on Patentability for PCT/US2014/022846 dated Sep. 15, 2015. 7 pages.
International Preliminary Report on Patentability for PCT/US2014/022742 dated Sep. 15, 2015. 7 pages.
International Preliminary Report on Patentability for PCT/US2014/022733 dated Sep. 15, 2015. 11 pages.
International Preliminary Report on Patentability for PCT/US2014/022769 dated Sep. 15, 2015. 8 pages.
International Search Report and Written Opinion dated Aug. 19, 2014 for PCT Application No. PCT/US2014/022736. 14 pages.
International Search Report and Written Opinion dated Aug. 27, 2014 for PCT Application No. PCT/US2014/022742. 11 pages.
International Search Report and Written Opinion dated Aug. 4, 2017 for PCT Application No. PCT/US2017/032104. 10 pages.
International Search Report and Written Opinion dated Dec. 8, 2014 for PCT Application No. PCT/US2014/052575. 10 pages.
International Search Report and Written Opinion dated Jan. 22, 2018 for PCT Application No. PCT/US2017/056352. 12 pages.
International Search Report and Written Opinion dated Jul. 22, 2014 for PCT Application No. PCT/US2014/022846. 11 pages.
International Search Report and Written Opinion dated Jul. 30, 2014 for PCT Application No. PCT/US2014/029682. 16 pages.
International Search Report and Written Opinion dated Jul. 31, 2014 for PCT Application No. PCT/US2014/022789. 13 pages.
International Search Report and Written Opinion dated Jul. 4, 2014 for PCT Application No. PCT/US2014/022769. 11 pages.
International Search Report and Written Opinion dated Mar. 5, 2013 for PCT Application No. PCT/US2012/072177. 7 pages.
International Search Report and Written Opinion dated May 11, 2015 for PCT Application No. PCT/US2015/014589. 5 pages.
International Search Report and Written Opinion dated May 20, 2013 for PCT Application No. PCT/US2012/072183. 11 pages.
International Search Report and Written Opinion dated Nov. 28, 2014 for PCT Application No. PCT/US2014/052576. 10 pages.
International Search Report and Written Opinion dated Oct. 31, 2014 for PCT Application No. PCT/US2014/013575. 10 pages.
Israel office action dated Aug. 11, 2016 for Israeli Patent Application No. 233329.
Ito et al., A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals,01D Cancer Science, Jan. 2003, 94, pp. 3-8.
Ivanisevic, et al. Uses of x-ray powder diffraction in the pharmaceutical industry. Pharm. Sci. Encycl. 2010; 1-42.
Jain, et al., “Polymorphism in Pharmacy”, Indian Drugs, 1986, 23(6) 315-329.
Jarvest et al., “Discovery and optimisation of potent, selective, ethanolamine Inhibitors of bacterial phenylalanyl tRNA synthetase”, Bioorganic & Medicinal Chemistry Letter (2005), 15(9), 2305-2309 CODEN: BMCLES; ISSN: 0960-894X.
Karche et al., “Electronic Effects in Migratory Groups [1,4]- versus [1,2]- Rearrangement in Rhodium Carbenoid Generated Bicyclic Oxonium Ylides”, Journal of Organic Chemistry (2001), 66(19), 6323-6332 CODEN: JOCEAH; ISSN: 0022-3263.
Katritzky et al., “Syntheses of 3-hydroxymethyl-2-3-dihydrobenzofurans and 3-hydroxymethylbenzofurans”, ARKIVOC (Gainesville, FL, United States) (2003), (6), 49-61 CODEN: AGFUAR URL: http://www.arkat-usa.org/ark/journal/2003/Vargoglis/AV-622A/6ss.pdf.
Kaye et al., “DABCO-catalyzed reactions of salicylaldehydes with acrylate derivatives”, Synthetic Communications (1996), 26(11), 2085-97 CODEN: SYNCAV; ISSN: 0039-7911.
Kaye et al., “Does the DABCO-catalyzed reaction of 2-hydroxybenzaldehydes with methyl acrylate follow a Baylis-Hillman pathway?”, Organic & Biomolecular Chemistry (2003), 1(7), 1133-1138 CODEN: OBCRAK; ISSN: 1477-0520.
Keidan, et al. Effect of BW12C on oxygen affinity of hemoglobin in sickle-cell disease. The Lancet. 1986; 327(8485):831-834.
Kessar et al., “Synthesis of Isoindolobenzazepines via photocyclisation of N-(2-formylphenethyl)phthalimide derivatives”, Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1991), 30B(11), 999-1005 CODEN: JSBDB; ISSN:3076-4699.
Kessar et al., An Interesting Application of Photocyclisation in Apophdeadane Alkaloid Synthesis. Tetrahedron Letters (1987), 28(44), 5323-5326. CODEN: TELEAY; ISSN: 0040-4039.
Kirk-Othmer Encyclopedia of Chemical Technology. 2002; 8:95-147.
Kise et al., “Electroreductive Intramolecular Coupling of Phthalimides with Aromatic Aldehydes: Application to the Synthesis of Lennoxamine”. Journal of Organic Chemistry (2011), 76(23), 9856-9880 CODEN:JOCEAH; ISSN: 0022-3263.
Klis, et al. Halogen-lithium exchange versus deprotonation: synthesis of diboronic acids derived from aryl-benzyl ethers. Tetrahedron Letters, 48(7):1169-1173 (2007).
Kratochvil. Chapter 8 Solid Forms of Pharmaceutical Molecules. J. Sestak et al. (eds.), Glassy, Amorphous and Nano-Crystalline Materials. Hot Topics in Thermal Analysis and Calorimetry 8, 2011, pp. 129-140.
Kraus, et al. Michael additions in anhydrous media. A novel synthesis of oxygenated coumarins. J. Org. Chem., 1979, 44 (14), pp. 2480-2482.
Krow,“The Baeyer-Villiger oxidation of ketones and aldehydes”, Organic Reactions (Hoboken, NJ, United States) (1993), 43, No pp. given CODEN: ORHNBA URL: http://www3.interscience.wiley.com/cgi-bin/mrwhome/107610747/HOME.
Kucera, et al. Evaluation of Ceolus(TM) microcrystalline cellulose grades for the direct compression of enteric-coated pellets. Drug Development and Industrial Pharmacy. Mar. 1, 2012; 38(3):341-350.
Lakkannavar et al., “4-[2′-benzylideneanlino aryloxymethyl] coumarins E and Z isomers”. Indian Journal of Heterocyclic Chemistry (1995), 4(4), 303-4 CODEN: IJCHEI; ISSN: 0971-1627.
Lin et al. Synthesis and anticancer activity of benzyloxybenzaldehyde derivatives against HL-60 cells. Bioorganic & Medicinal Chemistry. 13(5), 1537-1544 (2005).
Lin et al., “Potential Antitumor Agents.8. Derivatives of 3- and 5-Benzyloxy-2-formylpyridine Thiosemicarbazone”, Journal of Medicinal Chemistry, American Chemical Society, US, 1972, vol. 15, No. 6, pp. 615-618.
Liu et al., “Synthesis of Double-Armed Benzo- 15-crown-5 and Their Complexation Thermodynamics with Alkali Cations”, Journal of Inclusion Phenomena and Macrocyclic Chemistry (2005), 52(3-4), 229-235 CODEN: JIPCF5; ISSN: 1388-3127.
Luan, et al. TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases. Bioorganic & Medicinal Chemistry. 2013; 21:1870-1879.
Mahoney et al., “Functionalization of Csp3-H bond-Sc(OTf)3-catalyzed domino 1,5-hydride shift/cyclization/Friedel-Crafts acylation reaction of benzylidene Meldrum's acids”, Tetrahedron Letters (2009), 50(33), 4706-4709 CODEN: TELEAY; ISSN: 0040-4039.
Majhi et al., “An efficient synthesis of novel dibenzo-fused nine-membered oxacycles using a sequential Baylis-Hillman reaction and radical cyclization”, Synthesis (2008), (1), 94-100 CODEN: SYNTBF; ISSN: 0039-7881.
Manna et al., Synthesis and beta-adrenoreceptor blocking activity of [[3-(alkylamine)-2-hydroxypropyl]oximino]pyridines and 0[3-(alkylamine)-2-hydroxypropyl]methylpyridine ketone oximes derivatives, Il Farmaco, 1996, vol. 51, No. 8, 9, pp. 579-587.
Mantyla et al., Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J. Med. Chem. 2004, 47:188-195.
Marchetti et al., “Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors,” Org. Biomol. Chem, 2010, vol. 8, pp. 2397-2407.
“Master of Engineering Education Chemical Engineering Development Report” National Engineering Education Master in Chemical Engineering Cooperation Group, Zhejiang University Press. Mar. 31, 2011; 241-245. (in Chinese with English abstract).
Mathur. “Microcrystalline Cellulose” In: “Handbook of Pharmaceutical Excipients, Second Edition”, Jan. 1, 1994, The Pharmaceutical Press, London, pp. 84-87.
McKay et al., 7,11,15,28- Tetrakis[(2-formylphenoxy)methyl]- 1,21,23,25- tetramethylresorcin[4]arene cavitand ethyl acetate clathrate at 173 K, Acta Crystallographica, Section E: Structure Reports Online (2009), E65(4), 692-693 CODEN: ACSEBH; ISSN: 1600-5368 URL: http://journals.lucr.org/e/issues/2009/04/00fl22 33/fl2233.pdf.
McKay et al., “Microwave-assisted synthesis of a new series of resorcin[4]arene cavitand-capped porphyrin capsules”, Organic & Biomolecular Chemistry (2009), 7(19), 3958-3968 CODEN: OBCCRAK; ISSN: 1477-0520.
Merlino et al., “Development of second generation amidinohydrazones, thio- and semicarbazones as Trypanosoma cruzi-inhibitors bearing benzofuroxan and benzimidazole 1,3-dioxide core scaffolds”, MedChemComm (2010), 1(3), 216-228 CODEN: MCCEAY; ISSN: 2040-2503.
Mesguiche et al.,“4-Alkoxy-2,6-diaminopyrimidine Derivatives: Inhibitors of Cyclin Dependent Kinases 1 and 2,” Bioorganic & Medicinal Chemistry Letters, Jan. 2003, vol. 13, pp. 217-222.
Metcalf, et al., “Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin,” ACS Med. Chem. Lett., 2017, 8, 321-326.
Mitra et al., “Synthesis and biological evaluation of dibenz[b,f][1,5]oxazocine derivatives for agonist activity at x-opioid receptor”, European Journal of Medicinal Chemistry (2011), 46(5), 1713-1720 CODEN: EJMCA5; ISSN: 0223-5234.
Mulwad et al., “Synthesis and antimicrobial activity of [6′-methyl-4′-methoxy-2-oxo-2H-[1]-benzopyran)-2″,4″ dihydro-[1″,2″,4″}-triazol-3′ -one and 3′phenylthiazolidin-4′ -one-phenoxymethyl derivatives of dipyranoquinoline”, Pharmaceutical Chemistry Journal Ahead of Print CODEN: PCJOAU; ISSN: 0091-150, 2011; pp. 427-432.
Muzaffar, et al., “Polymorphism and Drug Availability: a Review” J of Pharm. (Lahore), 1979, 1(1), 59-66.
Nagy et al., Selective coupling of methotrexate to peptide hormone carriers through a y-carboxamide linkage of its glutamic acid moiety: Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling. Proc. Natl. Acad. Sci. USA 1993, 90:6373-6376.
Neelima et al., “A novel annelation reaction: synthesis of 6H-[1]benzopyrano[4,3-b]quinolines ”Chemistry & Industry (London, United Kingdom) (1986), (4), 141-2 CODEN: CHINAG; ISSN: 0009-3068.
Nnamani, et al., “Pyridyl derivatives of benzaldehyde as potential antisickling agents,” Chem. Biodivers., (2008), 5(9):1762-1769.
Nogrady, Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pp. 388-393 (1985).
Nonoyama et al.,“Cyclometallation of 2-(2-pyridyl)benzo[b]furen and 1-(2-pyridyl and 2-pyrimidyl)indole with palladium(II) and rhodium(III). Structures of unexpectedly formed nitro palladium(II) complexes”, Polyhedron 1999, 533-543 CODEN: PLYHDE; ISSN: 0277-5387.
Notice of Allowance dated Dec. 19, 2014 for U.S. Appl. No. 13/730,730. 11 pages.
Nyerges et al, “Synthesis of Indazole N-oxides via the 1,7-electrocyclization of azomethine ylides”, Tetrahedron Letters (2001), 42(30), 5081-5083 CODEN: TELEAY; ISSN:0040-4039.
Nyerges et al, “Synthesis of Indazole N-oxides via the 1,7-electrocyclization of azomethine ylides”, Tetrahedron Letters (2004), 60(44), 9937-9944 CODEN: TETRAB; ISSN:0040-4020.
OECD SIDS “SIDS Initial Assessment Report for 13th SIAM,” Nov. 2001, pp. 1-95.
Office Action dated Aug. 29, 2014 for U.S. Appl. No. 13/730,730. 17 pages.
Office Action dated Dec. 3, 2013 for U.S. Appl. No. 13/730,674. 8 pages.
Office Action dated Jul. 6, 2015 for U.S. Appl. No. 13/815,874. 14 pages.
Office Action dated Jun. 12, 2015 for CN Application No. 201280070743.5. 13 pages.
Office Action dated Jun. 29, 2015 for U.S. Appl. No. 13/815,810. 19 pages.
Office Action dated Jun. 30, 2014 for U.S. Appl. No. 13/730,674. 9 pages.
Office Action dated Sep. 18, 2013 for U.S. Appl. No. 13/730,674. 10 pages.
Oh, et al. Solid-phase synthesis of 1,3-oxazolidine derivatives. Tetrahedron Letters. 2000; 41:5069-5072.
O'Reilly, “Metal-phenoxyalkanoic acid interactions, XXV. The crystal structures of (2-formyl-6-methoxyphenoxy)acetic acid and its zinc(II)complex and the lithium, zinc(II) and cadmium(II) complexes of (2-chlorophenoxy)acetic acid”, Australian Journal of Chemistry (1987), 40(7)m 1146-59 CODEN; AJCHAS; ISSN:0004-9425.
Otsuka, et al., “Effect of Polymorphic Forms of Bulk Powders on Pharmaceutical Properties of Carbamazepine Granules.” Chem. Pharm. Bull., 47(6) 852-856 (1999).
Patani, et al. Bioisosterism: A Rational Approach in Drug Design. J. Chem Rev. 1996, 96(8), pp. 3147-3176.
Pearson, et al. Experimental and Computational Studies into an ATPH-Promoted exo-Selective IMDA Reaction: A Short Total Synthesis of Δ9-THC*. Chem. Eur. J. 2010, 16, 8280-8284.
Perez et al., “Preparation of new 1,2-disubstituted ferrocenyl ammonium salt”, Polyhedron (2009), 28(14), 3115-3119 CODEN: PLYHE; ISSN:0277-5387.
Perkins et al., “Manganese(II), Iron(II), cobalt(II), and cooper(II)complexes of an extended inherently chiral tris-bipyridyl cage”, Proceedings of the National Academy of Sciences of the United States of America (2006), 103(3), 532-537 CODEN: PNASA6; ISSN: 0027-8424.
Potapov, et al. A convenient synthesis of heterocyclic compounds containing 11-oxo-6,11,12,13-tetrahydrodibenzo[b,g][1,5]oxazonine fragment. Mendeleev Communications. 2009; 19:287-289.
Prohens, et al. Polymorphism in pharmaceutical industry. The Pharmacist. Apr. 1, 2007; 373:58-68. (in Spanish with English abstract).
PUBCHEM CID 54009805 Create Date: Dec. 4, 2011 p. 1.
PUBCHEM CID 54883281 Create Date: Aug 19, 2012 p. 1.
Remington's Pharmaceutical Sciences, 17th Edition, A. Gennaro editor, Easton Pennsylvania. Table of Contents. (1985).
Rodriguez-Spong, et al. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv Drug Deliv Rev. Feb. 23, 2004;56(3):241-74.
Rolan et al., “The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80); 4[2- formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects”, British Journal of Clinical Pharmacology, 1993, 35(4):419-425.
Rooseboom et al., Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 2004, 56:53-102.
Ruchirawat et al., “A novel synthesis of aporhoeadanes”, Tetrahedron Letters (1984), 25(32), 3485-8 CODEN: TELEAY; ISSN: 0040-4039.
Safo, et al. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds. J Med Chem. Sep. 9, 2004;47(19):4665-76.
Sahakitpichan et al., “A practical and highly efficient synthesis of lennoxamine and related isoindoloenzazepines” Tetrahedron (2004), 60(19), 4169-4172 CODEN: TETRAB; ISSN: 0040-4020.
Sahm et al., “Synthesis of 2-arylbenzofurans” Justus Liebigs Annalen der Chemie (1974), (4), 523-38 CODEN: JLACBF; ISSN: 0075-4617.
Sainsbury et al., “1,2-Dihydroisoquinolines, IV. Acylation” Tetrahedron (1966), 22(8), 2445-52 CODEN: TETRAB; ISSN: 0040-4020.
Sarodnick et al., “Quinoxalines XV, Convenient Synthesis and Structural Study of Pyrazolo[1,5-a]quinoxalines”, Journal of Organic Chemistry (2009), 74(3), 1282-1287 CODEN: JOCEAH; ISSN: 0022-3263.
Schudel, et al. Uber die Chemie des Vitamins E. Helvetica Chimica Acta. 1963; 66:636-649.
Seddon. Pseudopolymorph: A Polemic. The QUILL Centre, The Queen's University of Belfast, United Kingdom. Jul. 26, 2004. 2 pages.
Shetty et al. Palladium catalyzed alpha-arylation of methyl isobutyrate and isobutyronitrile: an efficient synthesis of 2,5-disubstituted benzyl alcohol and amine intermediates. Tetrahedron Letters, 47:8021-8024 (2006).
Siddiqui et al., “The Presence of Substitutents on the Aryl Moiety of the Aryl Phosphoramidate Derivative of d4T Enhances Anti-HIV Efficacy in Cell Culture-Activity Relationship,” J. Med. Chem., (1999), 42:393-399.
Silva et al., “Advances in prodrug design,” Mini Rev. Med. Chem., (2005), 5(10):893-914.
Singh et al., “Reductive-Cyclization-Mediated Synthesis of Fused Polycyclic Quinolines from Baylis-Hillman Adducts of Acrylonitrile: Scope and Limitations”, European Journal of Organic Chemistry (2009), (20), 3454-3466 CODEN: EJOCFK; ISSN:1434-193X.
Singhal, et al., “Drug Polymorphism and Dosage Form Design: a Practical Perspective” Advanced Drug Delivery reviews 56, p. 335-347 (2004).
Sobolev et al., Effect of acyl chain length and branching on the enantioselectivity of Candida rugosa lipase in the kinetic resolution of 4-(2-difluoromethoxyphenyl)-substituted 1,4-dihydropyridine 3,5-diesters. J. Org. Chem. 2002, 67:401-410.
Srivastava et al., “Synthesis and biological evaluation of 4-substituted tetrazolo[4,5-a]quinolines and 2,3-disubstituted quinoline derivatives”, Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1989), 28B(7), 562-73 CODEN: IJSBOB; ISSN:0376-4699.
Starke et al., “Quinoxalines, Part 13: Synthesis and mass spectrometric study of aryloxymethylquinoxalines and benzo[b]furylquinoxalines” Tetrahedron (2004), 60(29), 6063-6078 CODEN: TETRAB; ISSN:0040-4020.
Stetinova, et al. Synthesis and Properties of 4-Alkylaminomethyl and 4-Alkoxymethyl Derivatives of 5-Methyl-2-Furancarboxylic Acid. Collection Czechosloval Chem. Commun. 1985; 51:2186-2192.
STN Registry Database Entry: CAS RN 1039927-57-5 (Entered STN: Aug. 20, 2008).
STN Registry Database Entry: CAS RN 1243541-58-3 (Entered STN: Sep. 29, 2010).
Strickley. Solubilizing excipients in oral and injectable formulations. Pharm Res. Feb. 2004;21(2):201-30.
Swann et al., “Rates of reductive elimination of substituted nitrophenols from the (indol-3-yl)methyl position of indolequinones”, Journal of the Chemical Society, Perkin Transactions 2 (2001), (8), 1340-1345.
Table of Compounds, each of which can be found either in Table 1 of U.S. Pat. No. 9,018,210 or Table 1 of U.S. Pat. No. 9,012,450.
Taday, et al., “Using Terahertz Pulse Spectroscopy to Study the Crystalline Structure of a Drug: A Case Study of the Polymorphs of Ranitidine Hydrochloride.” J of Pharm. Sci., 92(4), 2003, 831-838.
Testa et al., Hydrolysis in Drug and Prodrug Metabolism, Jun. 2003, Wiley- VCH, Zurich, 419-534.
Tome et al., “Product class 13: 1,2,3-triazoles”, Science of Synthesis (2004), 13, 415-601 CODEN: SSCYJ9.
Tsuge, et al. Suppressive Effect of Vitamin B6-Sugar Derivatives on The Proliferation of Feline Mammary Tumor Cell, FRM. Vitamins (Japan), 2006; 80(11):537-542. (In Japanese with English Abstract).
U.S. Pharmacopia #23, National Formulary #18, 1995, 1843-1844.
Van Halbeek, et al., “Sialic Acid in Permethylation Analysis: Prepared and Identification of Partially O-Methylated Derivatives of methyl N-Acetyl-N-Methyl-beta-D-Neurominate Methyl Glycoside”, Carbohydrate Research, vol. 60, No. 1, 1978, pp. 51-62, 53, and 59.
vanRompaey et al., “A versatile synthesis of 2-substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepine-3-ones”, Tetrahedron (2003), 59(24), 4421-4432 CODEN: TETRAB; ISSN:0040-4020.
vanRompaey et al., “Synthesis and evaluation of the 3B2-turn properties of 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-ones and of their spirocyclic derivative”, European Journal of Organic Chemistry (2006), (13), 2899-2911 CODEN: EJOCFK; ISSN: 1434-193X.
Vicente et al., “Carbopalladation of Maleate and Fumarate Esters and 1,1-Dimethylallene with Ortho-Substituted Aryl Palladium Complexes” Organometallics (2010), 29(2), 409-416.
Vichinsky. “Emerging ‘A’ therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine.” Hematology 2012, 271-275.
Vippagunta, et al. Crystalline Solids. Advanced Drug Delivery Reviews. 2001; 48:3-26.
Wang et al., “Studies of Benzothiophene Template as Potent Factor IXa (FIXa) Inhibitors in Thrombosis”, Journal of Medicinal Chemistry (2010), 53, 1465-1472.
Warshawsky et al., “The synthesis of aminobenzazespinones as anti-phenylalanine dipeptide mimics and their use in NEP inhibition”, Bioorganic & Medicinal Chemistry Letter (1996), 6(8), 957-962 CODEN: BMCLE8; ISSN: 0960-894X.
Wendt et al., “Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists”, Bioorganic & Medicinal Chemistry Letters, Pergamon, Amsterdam, NL, vol. 17, No. 19, Sep. 14, 2007 (Sep. 14, 2007), pp. 5396-5399.
Wermuth, Camille G., “Molecular Variations Based on Isosteric Replacements”, The Practice of Medicinal Chemistry, 1996, pp. 203-232.
Yan et al., “Synthesis, crystal structure and antibacterial activity of dibutylitin carboxylate”, Huaxue Tongbao (2007), 70(4), 313-316 CODEN: HHTPAU; ISSN: 0441-3776.
Yan et al., “Synthesis, crystal structure and antibacterial activity of di-n-butyltin di-2(2-formylphenoxy)acetic ester”, Yingyong Huaxue (2007), 24(6), 660-664.
Yang, et al. Structural requirement of chalcones for the inhibitory activity of interleukin-5. Bioorg Med Chem. Jan. 1, 2007;15(1):104-11. Epub Oct. 10, 2006.
Yoon et al., The Chirality Conversion Reagent for Amino Acids Based on Salicyl Aldehyde. Bull. Korean Chem. Soc., (2012), 33:1715-1718.
Zhang et al., “DFT study on Rull-catalyzed cyclization of terminal alkynals to cycloalkenes”, International Journal of Quantum Chemistry (2009), 109(4), 679-687 CODEN: IJQCB2; ISSN:0020-7608.
Zhang, et al. A selective fluorescent chemosensor with 1, 2, 4-triazole as subunit for Cu (II) and its application in imaging Cu (II) in living cells. Dyes and Pigments. 2012; 92(3):1370-1375.
Zhang, et al. Current prodrug strategies for improving oral absorption of nucleoside analogues. Asian Journal of Pharmaceutical Sciences. Apr. 2014; 9(2):65-74.
Zhu et al., “Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity”, Bioorganic & Medicinal Chemistry Letters, Pergamon, Amsterdam, NL, 2006, vol. 16, No. 12, pp. 3150-3155.
Zwaagstra et al., “Synthesis and Structure-Activity Relationships of Carboxylated Chalcones: A Novel Series of Cys-LT1 (LTD4) Receptor Antagonists”, Journal of Medicinal Chemistry (1997), 40(7), 1075-1089 CODEN: JMCMAR; ISSN: 0022-2623.
Byrn, et al. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharmaceutical Research. 1995; 12(7):945-954.
Goodman and Gilman's The Pharmacological Basis of Therapeutics (Tenth Edition 2001), McGraw Hill. Chapter I, pp. 3-29.
Paul, et al. Hydroxyl directed C-arylation: synthesis of 3-hydroxyflavones and 2-phenyl-3-hydroxy pyran-4-ones under transition-metal free conditions. Org. Biomol. Chem., 2018, 16:444-451.
Ashizawa et al., Polymorphism and crystallization of the pharmaceutical drugs (Iyakuhin No Takeigensho to Shoseki No Kagaku) Maruzen Planet Co., Ltd., Sep. 20, 2002, pp. 3-16 and pp. 273-278. (in Japanese with partial English translation).
Beringer et al., Remington's Pharmaceutical Sciences, Mack Pub., 21st Edition, 2005, pp. 1072-1076.
“Can Voxelotor Offer New Hope for Sickle Cell Disease?,” Dec. 3, 2018, available at: https://www.ashclinicalnews.org/on-location/voxelotor-offers-new-hope-sickle-cell-disease/. 4 pages.
Experimental Chemistry (vol. 2)(Jikken Kagaku Koza, Zoku), Separation and refining, Maruzen Co.Ltd. Jan. 25, 1967, pp. 159-178 and pp. 186-187. (in Japanese with partial English translation).
GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease, Press Release dated Jun. 27, 2018. Available at http://ir.gbt.com/phoenix.zhtml?c=254105&p=irol-newsArticle&ID=2356168.
Gu, et al. Grouping solvents by statistical analysis of solvent property parameters: implication to polymorph screening. Int J Pharm. Sep. 28, 2004;283(1-2):117-25.
International Preliminary Report on Patentability dated Jun. 5, 2018 for PCT/US2016/064723. (10 pages).
International Search Report and Written Opinion dated May 3, 2017 for PCT Application No. PCT/US2016/064723. 15 pages.
Lehrer, et al. GBT440, a novel anti-polymerization agent, for the treatment of sickle cell disease. Global Blood Therapeutics. Apr. 1, 2016. (50 pages) Retrieved from the Internet: http://casicklecell.org/img/PresentationSlidesWebinar3.pdf.
New Introduction of Pharmacology (Sin Yakuzaigaku Soron)(revised 3rd Edition),Apr. 10, 1987, Nankodo Co., Ltd p. 111. (in Japanese with partial English translation).
New Pharmaceutical Preparation (Shin Seizaigaku), Nanzando Co.,Ltd., Apr. 25, 1984, p. 102-103 and pp. 232-233. (in Japanese with partial English translation).
Pharmacy -Foundation and Application-(Chozaigaku, Kiso to Ouyou), Nanzando Co.,Ltd., Sep. 20, 1977 p. 142-145. (in Japanese with partial English translation).
Reagan-Shaw, et al. Dose translation from animal to human studies revisited. The FASEB Journal. Mar. 2007; 22:659-661.
Shin, et al. Interpretation of Animal Dose and Human Equivalent Dose for Drug Development. The Journal of Korean Oriental Medicine. 2010; 31(3):1-7.
The Pharmacopoeia of Japan the Sixteen edition, 2011 pp. 64-68 2.58 X-ray powder diffraction measuring method p. 2070 (in Japanese with partial English translation).
Related Publications (1)
Number Date Country
20190106404 A1 Apr 2019 US
Provisional Applications (1)
Number Date Country
62335583 May 2016 US
Continuations (1)
Number Date Country
Parent 15593198 May 2017 US
Child 16101251 US